Communications about Evusheld between Professor James Palmer and the Antivirals and Therapeutics Taskforce

Department of Health and Social Care did not have the information requested.

Dear Department of Health and Social Care,

For the period 1 April 2022 to 6 September 2022

All direct communications between Professor James Palmer with the Antivirals and Therapeutics Taskforce (should this have its own email address or electronic identity) in which Evusheld (i.e. the combination of Tixagevimab and cilgavimab, AZD7742 or any other name that is used by the DHSC for this) is mentioned, whether by email or other electronic means.

Yours faithfully,

Louise Bicknell

Department of Health and Social Care

1 Attachment

Dear Ms Bicknell,

Please find attached the Department of Health and Social Care's response
to your recent FOI request (our ref: FOI-1428148).

Yours sincerely, 

Freedom of Information Team
Department of Health and Social Care

show quoted sections